Quick Answer
VYNE Therapeutics Inc. reported Long Term Debt of $0.00 for the year ending 2021.
- VYNE Therapeutics Inc. showed a decrease of -100.0% in Long Term Debt from 2020 to 2021.
- This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2022.
- XBRL data for this metric is available from 2019 to 2021 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $32.82 million | Q2 2020: $32.92 million | Q3 2020: $33.02 million | Q1 2021: $33.27 million | Q2 2021: $0.00 | Q3 2021: $0.00.
- Over the full 3 years of available data (2019 to 2021), VYNE Therapeutics Inc.'s Long Term Debt has declined by 100.0%.
- Historical annual values: Fiscal year 2021: $0.00 | Fiscal year 2020: $33.17 million | Fiscal year 2019: $32.73 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: